Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Information Circular posted
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(43)
•••
Comment by Lee430on Apr 17, 2021 11:26am
100 Views
Post# 33017069

RE:RE:RE:RE:RE:RE:RE:RE:Information Circular posted

RE:RE:RE:RE:RE:RE:RE:RE:Information Circular posted Palinc,
Initialy I was impressed that Molson was joining the BOD, now that the honeymoon is over I am not really sure what need he is filling, can someone speculate as to why he was added to the BOD and how such an expense was justified? 

palinc2000 wrote: The BOD in gneral is not impressive,,,,Most would fit well on the board of a retirement living community,,,,,,I know this is harsh but I think some younger still active and imaginative and demanding  board members would help create a better image,,,,I cant see how Levesque can have a good fit with the current members ...Arena is probably the only one picked by Levesque.

slso what does Molson bring to the table,,,,? Access to Montreal Canadians game!!! 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities